Engaging communities in tuberculosis research
Summary According to a growing consensus among biomedical researchers, community engagement can improve the ethics and outcomes of clinical trials. Although successful efforts to develop community engagement practices in HIV/AIDS research have been reported, little attention has been given to engage...
Gespeichert in:
| Veröffentlicht in: | The Lancet infectious diseases 2013-06, Vol.13 (6), p.540-545 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 545 |
|---|---|
| container_issue | 6 |
| container_start_page | 540 |
| container_title | The Lancet infectious diseases |
| container_volume | 13 |
| creator | Boulanger, Renaud F, BA Seidel, Stephanie, BA Lessem, Erica, MPH Pyne-Mercier, Lee, MPH Williams, Sharon D, BS Mingote, Laia Ruiz, BA Scott, Cherise, PhD Chou, Alicia Y, MS Lavery, James V, Dr |
| description | Summary According to a growing consensus among biomedical researchers, community engagement can improve the ethics and outcomes of clinical trials. Although successful efforts to develop community engagement practices in HIV/AIDS research have been reported, little attention has been given to engagement with the community in tuberculosis research. This article aims to draw attention to some existing community engagement initiatives in tuberculosis research and to resources that might help tuberculosis researchers to establish and implement community engagement programmes for their trials. One of these resources—the good participatory practice guidelines for tuberculosis drug trials—offers a conceptual framework and practical guidance for community engagement in tuberculosis research. To build momentum and to improve community engagement, lessons need to be shared, and formal assessment strategies for community engagement initiatives need to be developed. To build successfully on the promising activities described in this personal view, research funders and sponsors should show leadership in allocation of resources for the implementation and assessment of community engagement programmes in tuberculosis trials. |
| doi_str_mv | 10.1016/S1473-3099(13)70042-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1560124074</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1473309913700422</els_id><sourcerecordid>1560124074</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-268bd6360ef6a26d6bd5207ecd588c85de424de82ebaad3931c92c07a08f80633</originalsourceid><addsrcrecordid>eNqF0V9r1TAYBvAiDjenH0E5IMK86HzzP71RZEwdDHahXoc0eXvMbNOZtMK-venp0cFuzlVD-b1P8vJU1SsC5wSIfP-NcMVqBk1zRtg7BcBpTZ9UJ-U3rzkX6unuvJLj6nnOtwBEEeDPqmPKBCOsgZOqvoxbuw1xu3HjMMwxTAHzJsTNNLeY3NyPOeRNwow2uZ8vqqPO9hlf7r-n1Y_Pl98vvtbXN1-uLj5d146LZqqp1K2XTAJ20lLpZesFBYXOC62dFh455R41xdZazxpGXEMdKAu60yAZO63O1ty7NP6eMU9mCNlh39uI45wNERII5aD4YcoZaC6VIocpE4o3XEoo9M0jejvOKZadF8UZU5TSosSqXBpzTtiZuxQGm-4NAbO0ZHYtmaWCMmd2LZll7vU-fW4H9P-n_tVSwNs9sNnZvks2upAfnFpWl7q4j6vDUsafgMlkFzA69CGhm4wfw8GnfHiU4PoQQ7n0F95jftjaZGpgDVkyCNslUPYX2eC_4g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1354337222</pqid></control><display><type>article</type><title>Engaging communities in tuberculosis research</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Boulanger, Renaud F, BA ; Seidel, Stephanie, BA ; Lessem, Erica, MPH ; Pyne-Mercier, Lee, MPH ; Williams, Sharon D, BS ; Mingote, Laia Ruiz, BA ; Scott, Cherise, PhD ; Chou, Alicia Y, MS ; Lavery, James V, Dr</creator><creatorcontrib>Boulanger, Renaud F, BA ; Seidel, Stephanie, BA ; Lessem, Erica, MPH ; Pyne-Mercier, Lee, MPH ; Williams, Sharon D, BS ; Mingote, Laia Ruiz, BA ; Scott, Cherise, PhD ; Chou, Alicia Y, MS ; Lavery, James V, Dr ; on behalf of the Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup ; Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</creatorcontrib><description>Summary According to a growing consensus among biomedical researchers, community engagement can improve the ethics and outcomes of clinical trials. Although successful efforts to develop community engagement practices in HIV/AIDS research have been reported, little attention has been given to engagement with the community in tuberculosis research. This article aims to draw attention to some existing community engagement initiatives in tuberculosis research and to resources that might help tuberculosis researchers to establish and implement community engagement programmes for their trials. One of these resources—the good participatory practice guidelines for tuberculosis drug trials—offers a conceptual framework and practical guidance for community engagement in tuberculosis research. To build momentum and to improve community engagement, lessons need to be shared, and formal assessment strategies for community engagement initiatives need to be developed. To build successfully on the promising activities described in this personal view, research funders and sponsors should show leadership in allocation of resources for the implementation and assessment of community engagement programmes in tuberculosis trials.</description><identifier>ISSN: 1473-3099</identifier><identifier>EISSN: 1474-4457</identifier><identifier>DOI: 10.1016/S1473-3099(13)70042-2</identifier><identifier>PMID: 23531390</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>London: Elsevier Ltd</publisher><subject>Antitubercular Agents - standards ; Antitubercular Agents - therapeutic use ; Bacterial diseases ; Biological and medical sciences ; Biomedical Research ; Clinical Trials as Topic ; Community involvement ; Community-Based Participatory Research ; Consensus ; Cooperative Behavior ; Human bacterial diseases ; Human immunodeficiency virus ; Humans ; Infectious Disease ; Infectious diseases ; Medical sciences ; Mycobacterium ; Resource allocation ; Tuberculosis ; Tuberculosis - drug therapy ; Tuberculosis and atypical mycobacterial infections</subject><ispartof>The Lancet infectious diseases, 2013-06, Vol.13 (6), p.540-545</ispartof><rights>Elsevier Ltd</rights><rights>2013 Elsevier Ltd</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-268bd6360ef6a26d6bd5207ecd588c85de424de82ebaad3931c92c07a08f80633</citedby><cites>FETCH-LOGICAL-c459t-268bd6360ef6a26d6bd5207ecd588c85de424de82ebaad3931c92c07a08f80633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1473309913700422$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27407468$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23531390$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boulanger, Renaud F, BA</creatorcontrib><creatorcontrib>Seidel, Stephanie, BA</creatorcontrib><creatorcontrib>Lessem, Erica, MPH</creatorcontrib><creatorcontrib>Pyne-Mercier, Lee, MPH</creatorcontrib><creatorcontrib>Williams, Sharon D, BS</creatorcontrib><creatorcontrib>Mingote, Laia Ruiz, BA</creatorcontrib><creatorcontrib>Scott, Cherise, PhD</creatorcontrib><creatorcontrib>Chou, Alicia Y, MS</creatorcontrib><creatorcontrib>Lavery, James V, Dr</creatorcontrib><creatorcontrib>on behalf of the Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</creatorcontrib><creatorcontrib>Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</creatorcontrib><title>Engaging communities in tuberculosis research</title><title>The Lancet infectious diseases</title><addtitle>Lancet Infect Dis</addtitle><description>Summary According to a growing consensus among biomedical researchers, community engagement can improve the ethics and outcomes of clinical trials. Although successful efforts to develop community engagement practices in HIV/AIDS research have been reported, little attention has been given to engagement with the community in tuberculosis research. This article aims to draw attention to some existing community engagement initiatives in tuberculosis research and to resources that might help tuberculosis researchers to establish and implement community engagement programmes for their trials. One of these resources—the good participatory practice guidelines for tuberculosis drug trials—offers a conceptual framework and practical guidance for community engagement in tuberculosis research. To build momentum and to improve community engagement, lessons need to be shared, and formal assessment strategies for community engagement initiatives need to be developed. To build successfully on the promising activities described in this personal view, research funders and sponsors should show leadership in allocation of resources for the implementation and assessment of community engagement programmes in tuberculosis trials.</description><subject>Antitubercular Agents - standards</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Bacterial diseases</subject><subject>Biological and medical sciences</subject><subject>Biomedical Research</subject><subject>Clinical Trials as Topic</subject><subject>Community involvement</subject><subject>Community-Based Participatory Research</subject><subject>Consensus</subject><subject>Cooperative Behavior</subject><subject>Human bacterial diseases</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infectious Disease</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Mycobacterium</subject><subject>Resource allocation</subject><subject>Tuberculosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis and atypical mycobacterial infections</subject><issn>1473-3099</issn><issn>1474-4457</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0V9r1TAYBvAiDjenH0E5IMK86HzzP71RZEwdDHahXoc0eXvMbNOZtMK-venp0cFuzlVD-b1P8vJU1SsC5wSIfP-NcMVqBk1zRtg7BcBpTZ9UJ-U3rzkX6unuvJLj6nnOtwBEEeDPqmPKBCOsgZOqvoxbuw1xu3HjMMwxTAHzJsTNNLeY3NyPOeRNwow2uZ8vqqPO9hlf7r-n1Y_Pl98vvtbXN1-uLj5d146LZqqp1K2XTAJ20lLpZesFBYXOC62dFh455R41xdZazxpGXEMdKAu60yAZO63O1ty7NP6eMU9mCNlh39uI45wNERII5aD4YcoZaC6VIocpE4o3XEoo9M0jejvOKZadF8UZU5TSosSqXBpzTtiZuxQGm-4NAbO0ZHYtmaWCMmd2LZll7vU-fW4H9P-n_tVSwNs9sNnZvks2upAfnFpWl7q4j6vDUsafgMlkFzA69CGhm4wfw8GnfHiU4PoQQ7n0F95jftjaZGpgDVkyCNslUPYX2eC_4g</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Boulanger, Renaud F, BA</creator><creator>Seidel, Stephanie, BA</creator><creator>Lessem, Erica, MPH</creator><creator>Pyne-Mercier, Lee, MPH</creator><creator>Williams, Sharon D, BS</creator><creator>Mingote, Laia Ruiz, BA</creator><creator>Scott, Cherise, PhD</creator><creator>Chou, Alicia Y, MS</creator><creator>Lavery, James V, Dr</creator><general>Elsevier Ltd</general><general>Lancet Publishing Group</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>201306</creationdate><title>Engaging communities in tuberculosis research</title><author>Boulanger, Renaud F, BA ; Seidel, Stephanie, BA ; Lessem, Erica, MPH ; Pyne-Mercier, Lee, MPH ; Williams, Sharon D, BS ; Mingote, Laia Ruiz, BA ; Scott, Cherise, PhD ; Chou, Alicia Y, MS ; Lavery, James V, Dr</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-268bd6360ef6a26d6bd5207ecd588c85de424de82ebaad3931c92c07a08f80633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antitubercular Agents - standards</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Bacterial diseases</topic><topic>Biological and medical sciences</topic><topic>Biomedical Research</topic><topic>Clinical Trials as Topic</topic><topic>Community involvement</topic><topic>Community-Based Participatory Research</topic><topic>Consensus</topic><topic>Cooperative Behavior</topic><topic>Human bacterial diseases</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infectious Disease</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Mycobacterium</topic><topic>Resource allocation</topic><topic>Tuberculosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis and atypical mycobacterial infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boulanger, Renaud F, BA</creatorcontrib><creatorcontrib>Seidel, Stephanie, BA</creatorcontrib><creatorcontrib>Lessem, Erica, MPH</creatorcontrib><creatorcontrib>Pyne-Mercier, Lee, MPH</creatorcontrib><creatorcontrib>Williams, Sharon D, BS</creatorcontrib><creatorcontrib>Mingote, Laia Ruiz, BA</creatorcontrib><creatorcontrib>Scott, Cherise, PhD</creatorcontrib><creatorcontrib>Chou, Alicia Y, MS</creatorcontrib><creatorcontrib>Lavery, James V, Dr</creatorcontrib><creatorcontrib>on behalf of the Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</creatorcontrib><creatorcontrib>Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boulanger, Renaud F, BA</au><au>Seidel, Stephanie, BA</au><au>Lessem, Erica, MPH</au><au>Pyne-Mercier, Lee, MPH</au><au>Williams, Sharon D, BS</au><au>Mingote, Laia Ruiz, BA</au><au>Scott, Cherise, PhD</au><au>Chou, Alicia Y, MS</au><au>Lavery, James V, Dr</au><aucorp>on behalf of the Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</aucorp><aucorp>Critical Path to TB Drug Regimens' Stakeholder and Community Engagement Workgroup</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Engaging communities in tuberculosis research</atitle><jtitle>The Lancet infectious diseases</jtitle><addtitle>Lancet Infect Dis</addtitle><date>2013-06</date><risdate>2013</risdate><volume>13</volume><issue>6</issue><spage>540</spage><epage>545</epage><pages>540-545</pages><issn>1473-3099</issn><eissn>1474-4457</eissn><coden>LANCAO</coden><abstract>Summary According to a growing consensus among biomedical researchers, community engagement can improve the ethics and outcomes of clinical trials. Although successful efforts to develop community engagement practices in HIV/AIDS research have been reported, little attention has been given to engagement with the community in tuberculosis research. This article aims to draw attention to some existing community engagement initiatives in tuberculosis research and to resources that might help tuberculosis researchers to establish and implement community engagement programmes for their trials. One of these resources—the good participatory practice guidelines for tuberculosis drug trials—offers a conceptual framework and practical guidance for community engagement in tuberculosis research. To build momentum and to improve community engagement, lessons need to be shared, and formal assessment strategies for community engagement initiatives need to be developed. To build successfully on the promising activities described in this personal view, research funders and sponsors should show leadership in allocation of resources for the implementation and assessment of community engagement programmes in tuberculosis trials.</abstract><cop>London</cop><pub>Elsevier Ltd</pub><pmid>23531390</pmid><doi>10.1016/S1473-3099(13)70042-2</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1473-3099 |
| ispartof | The Lancet infectious diseases, 2013-06, Vol.13 (6), p.540-545 |
| issn | 1473-3099 1474-4457 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1560124074 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Antitubercular Agents - standards Antitubercular Agents - therapeutic use Bacterial diseases Biological and medical sciences Biomedical Research Clinical Trials as Topic Community involvement Community-Based Participatory Research Consensus Cooperative Behavior Human bacterial diseases Human immunodeficiency virus Humans Infectious Disease Infectious diseases Medical sciences Mycobacterium Resource allocation Tuberculosis Tuberculosis - drug therapy Tuberculosis and atypical mycobacterial infections |
| title | Engaging communities in tuberculosis research |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A00%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Engaging%20communities%20in%20tuberculosis%20research&rft.jtitle=The%20Lancet%20infectious%20diseases&rft.au=Boulanger,%20Renaud%20F,%20BA&rft.aucorp=on%20behalf%20of%20the%20Critical%20Path%20to%20TB%20Drug%20Regimens'%20Stakeholder%20and%20Community%20Engagement%20Workgroup&rft.date=2013-06&rft.volume=13&rft.issue=6&rft.spage=540&rft.epage=545&rft.pages=540-545&rft.issn=1473-3099&rft.eissn=1474-4457&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1473-3099(13)70042-2&rft_dat=%3Cproquest_cross%3E1560124074%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1354337222&rft_id=info:pmid/23531390&rft_els_id=1_s2_0_S1473309913700422&rfr_iscdi=true |